Altimmune, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting a net loss of $22,825 thousand for the three months ended June 30, 2026 and disclosing a significant increase in total assets driven by capital-raising activity.

Key Highlights

  • Net loss: Altimmune reported a net loss of $22,825 thousand for Q2 2026, compared to a net loss of $22,146 thousand in Q2 2025.
  • Six-month net loss: For the six months ended June 30, 2026, the company reported a net loss of $45,388 thousand, versus $41,721 thousand for the same period in 2025.
  • Total assets: Total assets were $527,212 thousand as of June 30, 2026, up from $279,929 thousand at December 31, 2025.
  • Shares outstanding: Common stock shares issued and outstanding totaled 194,474,154 as of June 30, 2026, compared to 110,882,735 at December 31, 2025.
  • Public offering: During Q2 2026, the company recorded net proceeds of $180,763 thousand from issuance of common stock in a public offering, and $30,300 thousand from issuance of pre-funded warrants in the same offering, according to the statements of changes in stockholders' equity.
  • Cash and investments: Cash and cash equivalents stood at $63,008 thousand and short-term investments at $263,273 thousand as of June 30, 2026.
  • Loss per share: Net loss per share, basic and diluted, was $0.12 for Q2 2026, compared to $0.27 for Q2 2025.

Altimmune's Financial Position and Operating Results for the Quarter Ended June 30, 2026

According to the filing, Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, reported total operating expenses of $26,229 thousand for Q2 2026, consisting of $18,655 thousand in research and development expenses and $7,574 thousand in general and administrative expenses. The company recorded no revenues for the three months ended June 30, 2026, compared to $5 thousand in the same period of 2025. Interest income of $4,526 thousand partially offset operating losses during the quarter, the filing disclosed.

The company's balance sheet reflected substantial growth in total assets, reaching $527,212 thousand as of June 30, 2026, up from $279,929 thousand at December 31, 2025. The filing attributed a significant portion of this increase to capital-raising activity completed during the first half of 2026. Long-term investments of $192,247 thousand appeared on the June 30, 2026 balance sheet, compared to zero at year-end 2025. Total stockholders' equity increased to $474,208 thousand from $224,892 thousand over the same period, according to the consolidated balance sheets.

For the six months ended June 30, 2026, total operating expenses were $50,473 thousand, with research and development comprising $34,847 thousand and general and administrative expenses totaling $15,626 thousand. The accumulated deficit stood at $694,871 thousand as of June 30, 2026, the filing reported. The weighted-average common shares outstanding, basic and diluted, for the six months ended June 30, 2026 were 155,121,235, compared to 78,529,028 for the same period in 2025, reflecting the share count growth from equity issuances during the period.

What Was Disclosed

Altimmune filed its unaudited quarterly report covering the period ended June 30, 2026, disclosing a Q2 net loss of $22,825 thousand, total assets of $527,212 thousand, significant equity issuances including a public offering and pre-funded warrants, and an accumulated deficit of $694,871 thousand.